News and press releases

Streamlining development and assessment of biosimilar medicines

EMA is exploring improvements to the development and evaluation of biosimilar medicines, while upholding strict European Union (EU) safety standards. With over two decades of…

Apr 26, 2025 - 14:24
 0
Streamlining development and assessment of biosimilar medicines
EMA is exploring improvements to the development and evaluation of biosimilar medicines, while upholding strict European Union (EU) safety standards. With over two decades of…
Read More

Tags:

Previous Article

Clinical Trials Information System designated as WHO primary registry

Next Article

First report on EU-wide sales and use of antimicrobials in animals

Related Posts

EMA business hours over Easter holiday period

EMA business hours over Easter holiday period

Apr 26, 2025  0

Clinical Trials Information System designated as WHO primary registry

Clinical Trials Information System designated as WHO pr...

Apr 26, 2025  0

Tackling vulnerabilities in the supply chain of radiopharmaceuticals in the EU

Tackling vulnerabilities in the supply chain of radioph...

Apr 26, 2025  0